Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock closed at $34.12 on 11/27/23 after a major increase of 17.8%. The stock has performed in line with the market over the last nine months and has risen 18.9% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, XENE is expected to be a modest Value Eraser.
Xenon Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Xenon Pharmaceuticals has a slightly negative Power Rating of 32 and a very low Appreciation Score of 15, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment